Assistant Professor
University of Nebraska Medical Center
I, Brady Sillman PhD, am a second-year Assistant Professor of Pharmacology and Experimental Neuroscience (PEN Department) at the University of Nebraska Medical Center (UNMC) with research interests in the development of a comprehensive understanding of drug design, modification, and delivery. My academic training and research experience to date have provided me with an excellent background in chemistry, biology, virology, and neuroimmunology, including organic synthesis, medicinal and polymer chemistries, cell culture work, animal models, drug detection, and sensitive viral detection methods. My long-term research interests involve the development of a comprehensive understanding and treatment of human diseases with ultra-/long-acting medicines, including HIV/AIDS, opioid use disorder (OUD), and Alzheimer’s disease; with the potential to use the systems developed in the lab for many other drugs and diseases. In addition to making fundamental advances in the areas of synthesis, drug discovery, and formulation, I have taken advantage of the unique opportunities at UNMC and the PEN Department to strengthen my research network through interdisciplinary collaborations with Drs. Dash, Edagwa, Panja, Gendelman, and several other internal and external collaborators. The strong research program and infrastructure at UNMC and the PEN Department is something that few other programs enjoy and a major advantage towards the success of my Projects. My work thus far has already led to a very productive research publication record; including several high impact publications in Nature journals in 2018, '19, ’20, ’21, '22, and one currently under review, as well as JCI (2017) and PNAS (2023); and 1,107 citations across 17 career publications. Additionally, I serve as the Operations Manager of the Nebraska Nanomedicine Production Plant (NNPP) at UNMC – an FDA-compliant manufacturing facility available to University researchers and the public, utilizing both GLP-level and GMP-level labs to facilitate bench to bedside production of nanomedicines for research, preclinical, and clinical trials.